The value of 18F-FDG PET/CT imaging in breast cancer staging
The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contribut...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ulkem Yararbas [verfasserIn] Neslihan Cetin Avci [verfasserIn] Levent Yeniay [verfasserIn] Aziz Murat Argon [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Biomolecules & Biomedicine - Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023, 18(2018), 1 |
|---|---|
| Übergeordnetes Werk: |
volume:18 ; year:2018 ; number:1 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.17305/bjbms.2017.2179 |
|---|
| Katalog-ID: |
DOAJ044452462 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ044452462 | ||
| 003 | DE-627 | ||
| 005 | 20240413173830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.17305/bjbms.2017.2179 |2 doi | |
| 035 | |a (DE-627)DOAJ044452462 | ||
| 035 | |a (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 100 | 0 | |a Ulkem Yararbas |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The value of 18F-FDG PET/CT imaging in breast cancer staging |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Breast cancer staging | |
| 650 | 4 | |a 18F-FDG | |
| 650 | 4 | |a 18F-FDG PET/CT | |
| 653 | 0 | |a Biology (General) | |
| 700 | 0 | |a Neslihan Cetin Avci |e verfasserin |4 aut | |
| 700 | 0 | |a Levent Yeniay |e verfasserin |4 aut | |
| 700 | 0 | |a Aziz Murat Argon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Biomolecules & Biomedicine |d Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023 |g 18(2018), 1 |w (DE-627)DOAJ078593212 |x 2831090X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:1 |
| 856 | 4 | 0 | |u https://doi.org/10.17305/bjbms.2017.2179 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e |z kostenfrei |
| 856 | 4 | 0 | |u https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2831-0896 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2831-090X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 1 | ||
| author_variant |
u y uy n c a nca l y ly a m a ama |
|---|---|
| matchkey_str |
article:2831090X:2018----::hvlef8fgeciaignrat |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
QH |
| publishDate |
2018 |
| allfields |
10.17305/bjbms.2017.2179 doi (DE-627)DOAJ044452462 (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e DE-627 ger DE-627 rakwb eng QH301-705.5 Ulkem Yararbas verfasserin aut The value of 18F-FDG PET/CT imaging in breast cancer staging 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT Biology (General) Neslihan Cetin Avci verfasserin aut Levent Yeniay verfasserin aut Aziz Murat Argon verfasserin aut In Biomolecules & Biomedicine Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023 18(2018), 1 (DE-627)DOAJ078593212 2831090X nnns volume:18 year:2018 number:1 https://doi.org/10.17305/bjbms.2017.2179 kostenfrei https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e kostenfrei https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 kostenfrei https://doaj.org/toc/2831-0896 Journal toc kostenfrei https://doaj.org/toc/2831-090X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2018 1 |
| spelling |
10.17305/bjbms.2017.2179 doi (DE-627)DOAJ044452462 (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e DE-627 ger DE-627 rakwb eng QH301-705.5 Ulkem Yararbas verfasserin aut The value of 18F-FDG PET/CT imaging in breast cancer staging 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT Biology (General) Neslihan Cetin Avci verfasserin aut Levent Yeniay verfasserin aut Aziz Murat Argon verfasserin aut In Biomolecules & Biomedicine Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023 18(2018), 1 (DE-627)DOAJ078593212 2831090X nnns volume:18 year:2018 number:1 https://doi.org/10.17305/bjbms.2017.2179 kostenfrei https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e kostenfrei https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 kostenfrei https://doaj.org/toc/2831-0896 Journal toc kostenfrei https://doaj.org/toc/2831-090X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2018 1 |
| allfields_unstemmed |
10.17305/bjbms.2017.2179 doi (DE-627)DOAJ044452462 (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e DE-627 ger DE-627 rakwb eng QH301-705.5 Ulkem Yararbas verfasserin aut The value of 18F-FDG PET/CT imaging in breast cancer staging 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT Biology (General) Neslihan Cetin Avci verfasserin aut Levent Yeniay verfasserin aut Aziz Murat Argon verfasserin aut In Biomolecules & Biomedicine Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023 18(2018), 1 (DE-627)DOAJ078593212 2831090X nnns volume:18 year:2018 number:1 https://doi.org/10.17305/bjbms.2017.2179 kostenfrei https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e kostenfrei https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 kostenfrei https://doaj.org/toc/2831-0896 Journal toc kostenfrei https://doaj.org/toc/2831-090X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2018 1 |
| allfieldsGer |
10.17305/bjbms.2017.2179 doi (DE-627)DOAJ044452462 (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e DE-627 ger DE-627 rakwb eng QH301-705.5 Ulkem Yararbas verfasserin aut The value of 18F-FDG PET/CT imaging in breast cancer staging 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT Biology (General) Neslihan Cetin Avci verfasserin aut Levent Yeniay verfasserin aut Aziz Murat Argon verfasserin aut In Biomolecules & Biomedicine Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023 18(2018), 1 (DE-627)DOAJ078593212 2831090X nnns volume:18 year:2018 number:1 https://doi.org/10.17305/bjbms.2017.2179 kostenfrei https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e kostenfrei https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 kostenfrei https://doaj.org/toc/2831-0896 Journal toc kostenfrei https://doaj.org/toc/2831-090X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2018 1 |
| allfieldsSound |
10.17305/bjbms.2017.2179 doi (DE-627)DOAJ044452462 (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e DE-627 ger DE-627 rakwb eng QH301-705.5 Ulkem Yararbas verfasserin aut The value of 18F-FDG PET/CT imaging in breast cancer staging 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT Biology (General) Neslihan Cetin Avci verfasserin aut Levent Yeniay verfasserin aut Aziz Murat Argon verfasserin aut In Biomolecules & Biomedicine Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023 18(2018), 1 (DE-627)DOAJ078593212 2831090X nnns volume:18 year:2018 number:1 https://doi.org/10.17305/bjbms.2017.2179 kostenfrei https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e kostenfrei https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 kostenfrei https://doaj.org/toc/2831-0896 Journal toc kostenfrei https://doaj.org/toc/2831-090X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2018 1 |
| language |
English |
| source |
In Biomolecules & Biomedicine 18(2018), 1 volume:18 year:2018 number:1 |
| sourceStr |
In Biomolecules & Biomedicine 18(2018), 1 volume:18 year:2018 number:1 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT Biology (General) |
| isfreeaccess_bool |
true |
| container_title |
Biomolecules & Biomedicine |
| authorswithroles_txt_mv |
Ulkem Yararbas @@aut@@ Neslihan Cetin Avci @@aut@@ Levent Yeniay @@aut@@ Aziz Murat Argon @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
DOAJ078593212 |
| id |
DOAJ044452462 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ044452462</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413173830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17305/bjbms.2017.2179</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ044452462</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ulkem Yararbas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The value of 18F-FDG PET/CT imaging in breast cancer staging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer staging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">18F-FDG</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">18F-FDG PET/CT</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Neslihan Cetin Avci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Levent Yeniay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aziz Murat Argon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Biomolecules & Biomedicine</subfield><subfield code="d">Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023</subfield><subfield code="g">18(2018), 1</subfield><subfield code="w">(DE-627)DOAJ078593212</subfield><subfield code="x">2831090X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17305/bjbms.2017.2179</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2831-0896</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2831-090X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield></datafield></record></collection>
|
| callnumber-first |
Q - Science |
| author |
Ulkem Yararbas |
| spellingShingle |
Ulkem Yararbas misc QH301-705.5 misc Breast cancer misc Breast cancer staging misc 18F-FDG misc 18F-FDG PET/CT misc Biology (General) The value of 18F-FDG PET/CT imaging in breast cancer staging |
| authorStr |
Ulkem Yararbas |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)DOAJ078593212 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
QH301-705 |
| illustrated |
Not Illustrated |
| issn |
2831090X |
| topic_title |
QH301-705.5 The value of 18F-FDG PET/CT imaging in breast cancer staging Breast cancer Breast cancer staging 18F-FDG 18F-FDG PET/CT |
| topic |
misc QH301-705.5 misc Breast cancer misc Breast cancer staging misc 18F-FDG misc 18F-FDG PET/CT misc Biology (General) |
| topic_unstemmed |
misc QH301-705.5 misc Breast cancer misc Breast cancer staging misc 18F-FDG misc 18F-FDG PET/CT misc Biology (General) |
| topic_browse |
misc QH301-705.5 misc Breast cancer misc Breast cancer staging misc 18F-FDG misc 18F-FDG PET/CT misc Biology (General) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Biomolecules & Biomedicine |
| hierarchy_parent_id |
DOAJ078593212 |
| hierarchy_top_title |
Biomolecules & Biomedicine |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)DOAJ078593212 |
| title |
The value of 18F-FDG PET/CT imaging in breast cancer staging |
| ctrlnum |
(DE-627)DOAJ044452462 (DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e |
| title_full |
The value of 18F-FDG PET/CT imaging in breast cancer staging |
| author_sort |
Ulkem Yararbas |
| journal |
Biomolecules & Biomedicine |
| journalStr |
Biomolecules & Biomedicine |
| callnumber-first-code |
Q |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| author_browse |
Ulkem Yararbas Neslihan Cetin Avci Levent Yeniay Aziz Murat Argon |
| container_volume |
18 |
| class |
QH301-705.5 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ulkem Yararbas |
| doi_str_mv |
10.17305/bjbms.2017.2179 |
| author2-role |
verfasserin |
| title_sort |
value of 18f-fdg pet/ct imaging in breast cancer staging |
| callnumber |
QH301-705.5 |
| title_auth |
The value of 18F-FDG PET/CT imaging in breast cancer staging |
| abstract |
The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. |
| abstractGer |
The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. |
| abstract_unstemmed |
The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
The value of 18F-FDG PET/CT imaging in breast cancer staging |
| url |
https://doi.org/10.17305/bjbms.2017.2179 https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179 https://doaj.org/toc/2831-0896 https://doaj.org/toc/2831-090X |
| remote_bool |
true |
| author2 |
Neslihan Cetin Avci Levent Yeniay Aziz Murat Argon |
| author2Str |
Neslihan Cetin Avci Levent Yeniay Aziz Murat Argon |
| ppnlink |
DOAJ078593212 |
| callnumber-subject |
QH - Natural History and Biology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17305/bjbms.2017.2179 |
| callnumber-a |
QH301-705.5 |
| up_date |
2024-07-03T23:04:45.714Z |
| _version_ |
1803600931819880448 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ044452462</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413173830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17305/bjbms.2017.2179</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ044452462</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd5cd32f91cd347a5a8ab2cbe58c40b5e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ulkem Yararbas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The value of 18F-FDG PET/CT imaging in breast cancer staging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer staging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">18F-FDG</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">18F-FDG PET/CT</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Neslihan Cetin Avci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Levent Yeniay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aziz Murat Argon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Biomolecules & Biomedicine</subfield><subfield code="d">Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2023</subfield><subfield code="g">18(2018), 1</subfield><subfield code="w">(DE-627)DOAJ078593212</subfield><subfield code="x">2831090X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17305/bjbms.2017.2179</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d5cd32f91cd347a5a8ab2cbe58c40b5e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.bjbms.org/ojs/index.php/bjbms/article/view/2179</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2831-0896</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2831-090X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield></datafield></record></collection>
|
| score |
7.3980513 |